Education
About Us
Working with TipRanks
Follow Us
Celcuity Inc. (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
$106.04
-$0.35(-2.63%)
At close: 4:00 PM EST
$106.04
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$7.58 - $120.32
Previous CloseN/A
Volume14.25K
Average Volume (3M)643.27K
Market Cap
$4.91B
Enterprise Value$5.15B
Total Cash (Recent Filing)$454.98M
Total Debt (Recent Filing)$320.35M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Mar 25, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding46,271,260
10 Day Avg. Volume793,816
30 Day Avg. Volume643,269
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.47
Price to Sales (P/S)0.00
P/FCF Ratio-6.17
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.47K
Enterprise Value/Ebitda-38.02
Forecast
1Y Price Target
$149.00Price Target Upside40.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.02
Revenue Forecast (FY)$55.30M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyPivotal VIKTORIA-1 mutant cohort readout could confirm stronger efficacy and safety signals seen in earlier-stage mutant patients and in the wild-type cohort, supporting potential commercial upside.
Regulatory ProgressPriority review of the gedatolisib new drug application accelerates regulatory assessment and increases the likelihood of earlier market authorization.
Scientific CredibilityPublication of VIKTORIA-1 wild-type cohort results in the Journal of Clinical Oncology enhances scientific credibility and visibility with clinicians and investors.
Bears Say
Competitive RiskAnalyst updated assumptions after competitor clinical disclosures, indicating that rival trial outcomes may reduce projected market share and company valuation.
Disclosure And Investor TransparencyMultiple events closed to media and requiring contact with a sales representative suggest limited public disclosure, which can increase investor uncertainty and information asymmetry.
Policy And Geopolitical RiskWashington strategy sessions on geopolitical conflict, policy options and tariff updates highlight policy-driven risks that could disrupt supply chains, costs, or market access.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $7.58 and its highest was $120.31 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $4.91B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Mar 25, 2026 which is tomorrow.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on Nov 12, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.099.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.04.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 46,271,260 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 0.998%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$149.00 (40.51% Upside)
$149.00 (40.51% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
912.79%
12-Months-Change
Fundamentals
Return on Equity
-179.00%
Trailing 12-Months
Asset Growth
74.34%
Trailing 12-Months
Company Description
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong position for Celcuity, with significant clinical and regulatory progress, a solid financial foundation, and promising market potential. However, the increased financial loss and regulatory uncertainties present challenges that need to be addressed.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$149.00
▲(40.51% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―